key: cord-0885983-l5d1ohuz
authors: Li, Zhuo; Zaiser, Sarah A.; Shang, Pengcheng; Heiden, Dustin L.; Hajovsky, Heather; Katwal, Pratik; DeVries, Baylor; Baker, Jack; Richt, Juergen A.; Li, Yanhua; He, Biao; Fang, Ying; Huber, Victor C.
title: A chimeric influenza hemagglutinin delivered by parainfluenza virus 5 vector induces broadly protective immunity against genetically divergent influenza A H1 viruses in swine
date: 2020-09-18
journal: Vet Microbiol
DOI: 10.1016/j.vetmic.2020.108859
sha: c4343cf0b61ad41ec348da3fd42862b62c79f7e9
doc_id: 885983
cord_uid: l5d1ohuz

Pigs are an important reservoir for human influenza viruses, and influenza causes significant economic loss to the swine industry. As demonstrated during the 2009 H1N1 pandemic, control of swine influenza virus infection is a critical step toward blocking emergence of human influenza virus. An effective vaccine that can induce broadly protective immunity against heterologous influenza virus strains is critically needed. In our previous studies [McCormick et al., 2015; PLoS One, 10(6):e0127649], we used molecular breeding (DNA shuffling) strategies to increase the breadth of the variable and conserved epitopes expressed within a single influenza A virus chimeric hemagglutinin (HA) protein. Chimeric HAs were constructed using parental HAs from the 2009 pandemic virus and swine influenza viruses that had a history of zoonotic transmission to humans. In the current study, we used parainfluenza virus 5 (PIV-5) as a vector to express one of these chimeric HA antigens, HA-113. Recombinant PIV-5 expressing HA-113 (PIV5-113) were rescued, and immunogenicity and protective efficacy were tested in both mouse and pig models. The results showed that PIV5-113 can protect mice and pigs against challenge with viruses expressing parental HAs. The protective immunity was extended against other genetically diversified influenza H1-expressing viruses. Our work demonstrates that PIV5-based influenza vaccines are efficacious as vaccines for pigs. The PIV5 vaccine vector and chimeric HA-113 antigen are discussed in the context of the development of universal influenza vaccines and the potential contribution of PIV5-113 as a candidate universal vaccine.

Influenza viruses are associated with approximately 291,000-600,000 deaths annually worldwide (1) , and vaccines remain our best method for limiting influenza virus infections (2) (3) (4) .

In addition to inactivated influenza vaccines, which have been available in a variety of forms since the 1940's (5, 6) , vaccines created using live, attenuated influenza virus strains (7, 8) and recombinant hemagglutinin (HA) proteins are now available (9) (10) (11) . Despite this, influenza seasons can be marred by issues related to vaccine performance (12) , including those associated with vaccine production (13, 14) , immunogenicity (15, 16) , and mismatches with the circulating strains (17) . Work with influenza HA proteins, and antibody responses against these proteins, has led to an understanding of the antigenic sites within the globular head (18) (19) (20) (21) (22) , as well as more conserved epitopes within the stem or stalk domain (23) (24) (25) . However, all current vaccines that have been approved for use rely on the expression of HA proteins that match those of circulating virus isolates (8) . Future influenza vaccines should challenge the concept that the antigen used to induce immunity needs to resemble the HA protein of circulating viruses (26) (27) (28) .

In designing these new vaccines, we must consider whether host immune responses that target J o u r n a l P r e -p r o o f a limited number of conserved epitopes offer sufficient protection against the threat of influenza virus epidemics and pandemics.

Our previous work in influenza vaccine development has focused on application of molecular breeding (DNA shuffling) technology to create chimeric HA proteins that are capable of inducing broad immunity (29) . We specifically targeted the HA from the 2009 pandemic virus, as well as HAs from three additional swine influenza viruses that had a history of zoonotic transmission to humans. These four selected parental influenza A H1N1 strains, A/New Jersey/8/76 (NJ76, alpha clade), A/Iowa/1/06 (IA06, beta clade), A/Ohio/1/07 (OH07, gamma clade), and A/Tennessee/1-560/09 (TN09, npdm) viruses, represented distinct phylogenetic clades (30, 31) . Using the DNA shuffling approach, we generated a library of chimeric HA antigens that, when evaluated in mice using a DNA vaccine approach, yielded three chimeric HAs with the ability to induce immunity against all of the parental HAs. Among these chimeric HAs, the construct HA-113 showed similar levels of antibody response against all four parental HAs, but we were unable to express HA-113 as part of an influenza virion using reverse genetics approaches (29) .

In order to develop a vaccine product, a protein-expression vector is needed for safe and efficient delivery of the candidate vaccine antigen. Previous studies showed that parainfluenza virus 5 (PIV-5) has several characteristics that make it an attractive vector for vaccine delivery.

First, kennel cough vaccines containing live PIV-5 have been used in dogs for over 40 years without safety concern for either humans or animals. Second, PIV-5 can be produced at high titers in many cell types, including Vero cells, which have been approved for vaccine production G protein of rabies virus, the F protein of respiratory syncytial virus (RSV), or the spike protein of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) provided immunity in mice against avian H5N1, rabies virus, RSV, and MERS-CoV, respectively (37) (38) (39) (40) . Together, these results demonstrate that PIV-5 is an effective vaccine vector.

In the current study, recombinant PIV-5 was engineered to express chimeric HA-113 antigen (PIV5-113). Immunogenicity of PIV5-113 was initially evaluated using a murine challenge model, prior to assessment of protective immunity in a nursery pig model. The results show that PIV5-113 can induce protective immunity against a broad range of influenza viruses. This study opens opportunities to apply this vaccine platform for further development of universal vaccines against influenza virus infection.

Parental HA genes, DNA shuffling, and viral strains. 

The DNA sequence from the shuffled HA gene HA-113 was cloned as described (29) . To generate ZL402 (pPIV5-HA113-SH/HN) plasmid, the coding sequence of the chimeric HA protein HA-113 was inserted into the PIV5 genome between the small hydrophobic (SH) gene and the hemagglutinin-neuraminidase (HN) gene. The rescue of infectious recombinant PIV5 was performed as described previously (45) . Briefly, the plasmid pZL402, encoding the full-length genome of PIV5 with the HA113 gene inserted between the SH and HN genes, as well as three helper plasmids, pPIV5-NP, pPIV5-P, and pPIV5-L, encoding NP, P, and L proteins, respectively, were co-transfected into BSR T7 cells at 95% confluence in 6-cm plates. After 72 h of incubation at 37°C, the media were harvested and cell debris was pelleted by low-speed centrifugation 

The 8-plasmid reverse genetics system, incorporating the 293T (ATCC) and 

A total of 98 adult ( four weeks after boosting, and monitored daily for signs of morbidity and mortality, as described (46) (47) (48) . Mice were euthanized when they achieved humane endpoints, including weights equal to or below 80% of their initial body weight.

Hemagglutination inhibition (HAI) assays were performed, with receptor-destroying enzyme (RDE, Accurate Chemical, Westbury, NY) being used to treat serum samples prior to use in the HAI assay, as described previously (49) . RDE-treated serum samples from pigs (1 mL volume) were incubated with chicken red blood cells (50 L) to remove nonspecific agglutinins in the serum, as described (50, 51) . All RDE-treated sera were diluted, and 4 HA units of virus were added to each well. The virus:sera mixtures were incubated for one hour at 4°C, and a 0.5% solution of chicken red blood cells (Lampire Biological Laboratories, Pipersville, PA) was added J o u r n a l P r e -p r o o f to each well. Titers are reported as the reciprocal of the final serum dilution that inhibited hemagglutination. A titer of 5 was assigned to serum samples that did not demonstrate HAI at the starting serum dilution of 1:10.

Serum antibodies were detected using an ELISA, as described previously (29, 42, 47 

The 

Graphing and statistical analyses were performed using GraphPad Prism version 8 for

Windows (GraphPad Software, San Diego California USA, www.graphpad.com). Significance is reported at P<0.05, using the tests indicated.

tissue culture.

Recombinant PIV5-113 was constructed by inserting the HA113 gene into a plasmid containing the full-length cDNA genome of PIV5 at the junction between the SH and HN genes ( Fig. 1A) . Infectious PIV5-113 virus was recovered by transfecting the plasmid into BSR T7 cells along with plasmids carrying NP, P, and L genes as described previously (37) . The recovered virus was plaque-purified and grown in MDBK cells, and the full-length genome of plaque-purified virus was sequenced using direct reverse transcription-PCR (RT-PCR) sequencing. A single plaque-purified clone matching the exact cDNA of the genome sequence was used for subsequent experiments. To compare growth of PIV5 and PIV5-113 in tissue culture, multiplestep growth curves were performed using MDBK cells. PIV5-113 grew to similar titers as PIV5 at the indicated time points (Fig. 1B) .

J o u r n a l P r e -p r o o f

To assess the immunogenicity of PIV5-113, we initially tested this recombinant vaccine in mice. Three groups of mice were immunized with either PBS (negative control), PIV5 (vector control), or PIV5-113. Mice were boosted on day 28, and sera were collected three weeks after boosting. HAI assay results showed significantly increased titers (P<0.05) of HA-reactive antibodies against the parental viruses of chimeric HA113, including NJ76, IA06, OH07, and TN09

viruses in the group of mice vaccinated with PIV5-113, in comparison with serum from mice inoculated with either PBS or PIV5 vector alone (Fig. 2) . Sera were tested for reactivity with a non-parental virus, ME08 (delta clade) to determine the breadth of vaccine-induced immunity in PIV5-113-vaccinated mice. Vaccine-induced HA-reactive antibodies against ME08 were significantly increased in PIV5-vaccinated animals, but these levels were lower than those induced against the NJ76, IA06, OH07, and TN09 parental HAs.

To confirm results generated from HAI, we used an isotype-specific ELISA, which included tests for total antibody (IgG (H+L)), IgG1, and IgG2a (Fig. 3) . ELISA results showed a significant increase (P<0.05) in titers of IgG (H+L), IgG1, and IgG2a antibodies against NJ76, IA06, OH07, and TN09 viruses in PIV5-113-vaccinated mice compared to antibody responses in groups of mice inoculated with either PBS or PIV5 vector alone. Similar to the results from the HAI assay, antibodies against ME08 were detected by ELISA, this time at levels that were similar to those induced against IA06 and TN09.

Next, we challenged mice with the 4 different influenza viruses individually expressing the parental HA proteins used to create HA-113 ( Table 1) . These viruses were created by reverse genetics as described above, and they were designed so that they differ only in the HA expressed, with internal genes and neuraminidase being provided by the mouse-adapted influenza virus strain PR8 (42) . Our results show that PIV5-113-vaccinated mice were protected from challenge with viruses expressing the parental HAs of NJ76, IA06, OH07, and TN09. This was observed in J o u r n a l P r e -p r o o f both the weight loss (Fig. 4) and Kaplan-Meier survival curves (Fig. 5 ) generated after challenge.

In addition to the PIV5-113-vaccinated mice that survived lethal challenge, 2 out of 8 mice in the PIV5 alone group survived challenge with NJ76. This result might be due to increases in cellmediated immunity stimulated by PIV5, which is consistent with a result that had been previously reported in PIV5-immunized mice (52) . Mice that were vaccinated with PIV5-113 were not protected from challenge with the non-parental ME08 virus, which did not show strong antibody reactivity in the HAI assay (Fig. 2) .

Since Interestingly, similar to our findings in mice, antibodies against the non-parental ME08 were also significantly increased in the PIV5-113 vaccine group at DPC5, albeit at a lower level than antibodies against the parental HAs (Fig. 6A) .

Based on this finding, we decided to determine the breadth of PIV5-113-induced immunity by further testing the antibody response against an extended panel of viruses (Fig. 6B) . These viruses represent isolates that had been previously circulating in both pigs and humans, including the IA92 and CA09 viruses we tested previously (29) . In addition, we included the MI15 H1N1

virus isolate that was used in the 2018-19 Northern Hemisphere seasonal influenza vaccine (8) and a primary swine H1N1 virus (13E100) that was isolated during surveillance of pigs at a swine abattoir (53) . The HAI assay was performed using serum samples from all three groups of pigs, collected at DPC5. As shown in Fig. 6B , serum antibodies from PIV5-113-vaccinated pigs showed a significant increase (P<0.05) in HAI titer against the IA92, CA09, MI15, and 13E100

influenza viruses, suggesting the PIV5-113 is able to induce broad immunity against genetically diversified H1 viruses that circulate in both pigs and humans, including additional representatives of the alpha (IA92), npdm (CA09 and MI15), and gamma (13E100) H1 clades.

After challenge, PIV5-113-vaccinated pigs appeared to be protected from the challenge with the npdm H1 clade Alb09 virus, as evidenced by the absence of virus shedding in nasal secretions (Fig. 7) . In contrast, challenge virus was detected in pigs in the PBS and PIV5 vector groups as early as Day 3 post-challenge (Fig. 7B) . Subsequently, a significant increase (P<0.05) in virus was detected in nasal swab samples from all control pigs at Day 5 post-challenge (Fig.   7C ). To confirm virus infection of the lower respiratory tract, bronchoalveolar lavage fluid (BALF) was collected from all animals at DPC5 (Fig. 7D) . Pigs in the PBS and PIV5 groups showed detectable levels of virus in the BALF. In contrast, virus was not detected in BALF collected from PIV5-113-vaccinated pigs. Together, results from the nasal swab and BALF samples indicate that PIV5-113 induced protective immunity in vaccinated pigs, which protected pigs against influenza infection in both the upper and the lower respiratory tracts.

The current influenza vaccine selection process relies on surveillance to predict viruses that will circulate during the next influenza season, with selection of viruses that are predicted to match these viruses (54) (55) (56) . This process can be time-consuming and has not always been able to match viruses that arise from either antigenic drift during seasonal influenza virus circulation, or from the antigenic shift that initiates pandemics (57) (58) (59) . In pigs, annual updates for swine influenza vaccines is not economically feasible. Since influenza viruses associated with pandemics often come from a known source, with representative viruses circulating in birds and pigs prior to emergence in humans (60) (61) (62) , there is often knowledge of the viruses circulating in all three dominant species infected with influenza viruses (63) . This presents an opportunity to use this knowledge to design vaccines that prevent infection from interspecies transmission events. To use this knowledge to our advantage, our previous work showed that DNA shuffling could yield chimeric HAs as candidate vaccine antigens against genetically diversified influenza viruses that circulate in human and pigs. Using reverse genetics, we advanced one chimeric HA, identified as HA-129 into both the PR8 and the A/swine/Texas/4199-2/98 backbone (TX98-129)

to generate inactivated influenza virus (IIV) and live, attenuated influenza virus (LAIV) candidate vaccines (29) . Results from other chimeric HA proteins created from gene shuffling, including the chimeric HA-113, showed improved breadth of antigenicity, but we were unable to express these HAs using conventional IIV and LAIV vaccine production methods.

In the current study, we utilized PIV5 as a vector for delivery of HA-113 as a candidate vaccine, and evaluated induction of protective immunity in both mice and pigs. In summary, our previous work proved the concept that chimeric HA antigens generated by DNA shuffling could be used to induce broad immunity against genetically diversified influenza viruses that circulate in both pigs and humans; however, we were limited in our ability to express some of the best candidates within intact influenza virions (29) . In the current study, we demonstrate that PIV5 can be used to express a chimeric antigen, HA-113, and that immune responses induced by PIV5-113 are protective in both mice and pigs. We expect that the vaccine platform and technologies established in our studies can be applied to HA and NA proteins within different influenza A virus subtypes, including those that remain on our pandemic radar like H2N2, H5N1, and H7N9 (76, 77) . 

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

Global Funders Consortium for Universal Influenza Vaccine D. Global Funders Consortium for Universal Influenza Vaccine Development

Current and future influenza vaccines

Prevention and Control of Seasonal Influenza with Vaccines

History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines

Concentration and purification of influenza virus for the preparation of vaccines

Adaptation and growth characteristics of influenza virus at 25 degrees c

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States

Expression of the influenza virus haemagglutinin in insect cells by a baculovirus vector

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults

Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

Influenza H3N2 Vaccines: Recent Challenges

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses

Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013

Repeated annual influenza vaccination and vaccine effectiveness: review of evidence

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness

Selection of influenza A virus adsorptive mutants by growth in the presence of a mixture of monoclonal antihemagglutinin antibodies

Que sera, sera: evolution of the swine H1N1 influenza A virus

Mapping of antigenic changes in the haemagglutinin of Hong Kong influenza (H3N2) strains using a large panel of monoclonal antibodies

Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites

Mapping the antigenic and genetic evolution of influenza virus

Complete structure of the hemagglutinin gene from the human influenza A/Victoria/3/75 (H3N2) strain as determined from cloned DNA

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

Antibody recognition of a highly conserved influenza virus epitope

Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development

Vaccine options for influenza: thinking small

Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans

Construction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses

A Phylogeny-Based Global Nomenclature System and Automated Annotation Tool for H1

Influenza Research Database: An integrated bioinformatics resource for influenza virus research

The viruses and their replication

Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge

Isolation and molecular characterization of parainfluenza virus 5 in diarrhea-affected piglets in China

Complete genome sequence of a novel porcine parainfluenza virus 5 isolate in Korea

Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5

Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge

A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein

A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5)

Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection

Eight-plasmid system for rapid generation of influenza virus vaccines

A multi-valent vaccine approach that elicits broad immunity within an influenza subtype

Population dynamics of cocirculating swine influenza A viruses in the United States from 2009 to 2012. Influenza Other Respir Viruses

pandemic H1N1 influenza virus causes disease and upregulation of genes related to inflammatory and immune responses, cell death, and lipid metabolism in pigs

Recovery of infectious SV5 from cloned DNA and expression of a foreign gene

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections

Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays. Influenza Other Respi Viruses

A comparison of hemagglutination inhibition and neutralization assays for characterizing immunity to seasonal influenza A. Influenza Other Respir Viruses

Comparison of serological assays for detecting antibodies in ducks exposed to H5 subtype avian influenza virus

Efficacy of parainfluenza virus 5 mutants expressing hemagglutinin from H5N1 influenza A virus in mice

Development of a multiplex real-time RT-PCR assay for simultaneous detection and differentiation of influenza

Experience with Vaccination Against Influenza in the Spring of 1947: A Preliminary Report

Report of the Study Committee on Influenza Vaccination (The Present Status of Vaccination Against Influenza)

65 years of influenza surveillance by a World Health Organization-coordinated global network. Influenza Other Respir Viruses

Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982

The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic

Natural history of influenza type A in the United States

Molecular aspects of the epidemiology of virus disease

Distribution of sialic acid receptors and influenza A virus of avian and swine origin in experimentally infected pigs

Characterization of avian influenza virus attachment patterns to human and pig tissues

Evolution and ecology of influenza A viruses

Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner

Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets

Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses

A computationally optimized broadly reactive antigen (COBRA) based

H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets

Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus

Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice

Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses

Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge

Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice

Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses

Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice

A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge

Are we ready for pandemic influenza?

Influenza at the animalhuman interface: a review of the literature for virological evidence of human infection with swine